Reducing doctor and patient barriers to genomic (NGS) testing for metastatic prostate cancer
Official title: A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing
Run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07209176 · Data updated 2026-11-12
This project will try two approaches—supporting doctors and supporting patients—to increase genomic (NGS) testing for men with metastatic prostate cancer at Johns Hopkins.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 256 (estimated) |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | January 6, 2026 |
| Main results expected | September 6, 2027 |
| Study ends | September 6, 2027 |
| Registry record updated | February 3, 2026 |
| Trial ID | NCT07209176 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men with metastatic prostate cancer who are new patients in Johns Hopkins Medical Oncology between January 1, 2025 and December 31, 2026 and who have not yet had NGS testing are eligible.
✕Probably not a fit
Patients who have already had NGS testing performed or who do not receive care at Johns Hopkins are unlikely to benefit from this initiative.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
National guidelines recommend next-generation sequencing (NGS) for metastatic prostate cancer, but testing rates are low and around 50–60% at Johns Hopkins. This initiative uses a multidisciplinary quality-improvement approach that targets two barriers: provider-level and patient-level factors. Interventions include education and workflow changes for clinicians and tailored patient-facing supports, with measurement of NGS ordering rates before and after the interventions. The team aims to reduce disparities by focusing on groups less likely to be tested, such as older and unmarried patients.
Why it matters
Potential benefit: If successful, more patients would receive guideline-recommended genomic testing, improving treatment selection and access to clinical trials.
How similar studies have gone: Related provider- and patient-focused interventions have increased uptake of guideline testing in other settings, but this combined approach specifically for NGS in metastatic prostate cancer is relatively untested at Johns Hopkins.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * men diagnosed with metastatic prostate cancer * seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026 Exclusion Criteria: \- Patients who have already had NGS testing performed.
Where it's running
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Catherine Marshall, MD — Johns Hopkins University
- Study coordinator: Catherine Marshall, MD
- Email: chm@jhmi.edu
- Phone: 410-955-0231
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
JANX013 and JANX007 combo in advanced prostate cancer
A first-in-human study will test JANX013 together with JANX007 to see if this combination is safe and tolerable in adults with metastatic castration-resistant prostate cancer.
-
PSMA PET-Staged Progression-Directed Radiotherapy for Limited Prostate Cancer Progression
A real-world registry tests how well comprehensive progression-directed radiotherapy works for men with metastatic prostate cancer who show a small number of progressing lesions while on systemic therapy.
-
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
This registry follows men with new, limited metastatic prostate cancer who receive targeted radiotherapy to the prostate and all visible metastases to see how they do over time in real-world care.
-
PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer
This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.
-
First-in-human imaging test of the GRPR-targeted theranostic pair for advanced breast or prostate cancer
This early feasibility study tests a GRPR-targeted imaging agent for PET and a low-dose radiopharmaceutical for SPECT in adults with advanced breast or prostate cancer to see if it is safe and can image tumors.
-
Combined treatment approach in metastatic prostate cancer using AZD2265 (FPI-2265) with palacaparib or docetaxel
This study tests how AZD2265 (FPI-2265) with or without palacaparib or docetaxel works in men with metastatic castration-resistant prostate cancer who have already tried AR pathway inhibitors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.